MiNK Therapeutics (INKT) Change in Cash (2020 - 2026)

MiNK Therapeutics has reported Change in Cash for 7 years, with the latest figure at -$3.8 million in Q1 2026.

• Quarterly Change in Cash fell 185.71% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (up 343.62% YoY) and the FY2025 annual result came in at $8.8 million, up 626.01% from the prior year.
• Change in Cash retreated to -$3.8 million in Q1 2026 per INKT's latest filing, from -$920872.0 in the prior quarter.
• Over five years, Change in Cash peaked at $12.6 million in Q3 2025 and troughed at -$5.7 million in Q3 2022.
• A 5-year average of -$1.7 million and a median of -$3.0 million in 2023 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2025: Change in Cash plunged 670.89% in 2022, then jumped 522.03% in 2025.
• Over 5 years, Change in Cash stood at -$4.5 million in 2022, then soared by 32.97% to -$3.0 million in 2023, then jumped by 42.24% to -$1.8 million in 2024, then soared by 47.41% to -$920872.0 in 2025, then tumbled by 316.42% to -$3.8 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$3.8 million, -$920872.0, and $12.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.